Viavi price target raised to $42 from $27 at Rosenblatt

Rosenblatt analyst Mike Genovese raised the firm’s price target on Viavi (VIAV) to $42 from $27 and keeps a Buy rating on the shares following an “upbeat” meeting with management at the OFC trade show. The firm, which sees multiple drivers of upside at Viavi, notes that its FY27 EPS estimate of $1.50 is a “solid upside scenario versus consensus at $1.01, but below the most bullish scenario of $2 in FY27 earning power.”